What we are studying
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body’s immune system to work against tumor cells. It has been approved by the FDA for the treatment of metastatic melanoma (a type of skin cancer), and specific types of previously treated advanced lung and kidney cancers.
The effectiveness of nivolumab in relapsed or refractory multiple myeloma (rrMM) will be determined by comparing the change in tumor burden and progression free survival of subjects who receive nivolumab combined pomalidomide and dexamethasone compared with those who receive pomalidomide and dexamethasone only. Pomalidomide is an approved treatment for multiple myeloma often given in combination with dexamethasone, a steroid. The combination of pomalidomide and dexamethasone is an accepted standard of care therapy.
This study will also examine the tumor burden and progression free survival of subjects given nivolumab combined with elotuzumab, pomalidomide, and dexamethasone. Elotuzumab is a manufactured protein directed against a target found on multiple myeloma cells. It is an approved treatment for multiple myeloma patients whose disease worsens after the initial treatment.
The participant will receive $53 for every completed visit. The study participant will be issued a specially designed debit card for clinical research onto which funds will be loaded at the completion of the visit.